key: cord-0749902-hz0y6azl
authors: Gupta, Yash; Maciorowski, Dawid; Zak, Samantha E.; Jones, Krysten A.; Kathayat, Rahul S.; Azizi, Saara-Anne; Mathur, Raman; Pearce, Catherine M; Ilc, David J.; Husein, Hamza; Herbert, Andrew S.; Bharti, Ajay; Rathi, Brijesh; Durvasula, Ravi; Becker, Daniel P.; Dickinson, Bryan C.; Dye, John M.; Kempaiah, Prakasha
title: Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays
date: 2021-01-14
journal: Methods
DOI: 10.1016/j.ymeth.2021.01.003
sha: 0753087c76cc7a239c54a7a0f51d6c0d5f4b9e2d
doc_id: 749902
cord_uid: hz0y6azl

SARS-CoV-2, the virus that causes COVID-19 consists of several enzymes with essential functions within its proteome. Here, we focused on repurposing approved and investigational drugs/compounds. We targeted seven proteins with enzymatic activities known to be essential at different stages of the viral cycle including PLpro, 3CLpro, RdRP, Helicase, ExoN, NendoU, and 2’-O-MT. For virtual screening, energy minimization of a crystal structure of the modeled protein was carried out using the Protein Preparation Wizard (Schrodinger LLC 2020-1). Following active site selection based on data mining and COACH predictions, we performed a high-throughput virtual screen of drugs and investigational molecules (n=5903). The screening was performed against viral targets using three sequential docking modes (i.e., HTVS, SP, and XP). Virtual screening identified ∼290 potential inhibitors based on the criteria of energy, docking parameters, ligand, and binding site strain and score. Drugs specific to each target protein were further analyzed for binding free energy perturbation by molecular mechanics (prime MM-GBSA) and pruning the hits to the top 32 candidates. The top lead from each target pool was further subjected to molecular dynamics simulation using the Desmond module. The resulting top eight hits were tested for their SARS-CoV-2 anti-viral activity in-vitro. Among these, a known inhibitor of protein kinase C isoforms, Bisindolylmaleimide IX (BIM IX), was found to be a potent inhibitor of SARS-CoV-2. Further, target validation through enzymatic assays confirmed 3CLpro to be the target. This is the first study that has showcased BIM IX as a COVID-19 inhibitor thereby validating our pipeline.

site strain energies, and fit score. Compounds specific to each target protein were further analyzed for binding free energy perturbation by the molecular mechanics' method using Prime MM-GBSA [10] , followed by refining the hits to the best 32 lead candidates. A top-scoring lead from each target group was further subjected to a molecular dynamic simulation (MDS) using the Desmond module [10] to validate the screening pipeline (Overall Study Design; Fig1).

Drug Repurposing for COVID-19: While drugs have initially been produced for use against a specific target and disease, drug repurposing offers a new and faster approach to initiate researchbased methodologies. The utility of protein modeling and molecular docking has shown that approved drugs specified for certain indications can have a significant impact on other diseases [12] . For example, loperamide is an approved drug for controlling acute and chronic diarrhea that has exhibited inhibition of the MERS-CoV replication cycle [13] . Several studies are currently in progress exploring the use of antiviral drugs that were approved for influenza, hepatitis C virus, and human immunodeficiency virus (HIV) 1 against COVID-19, though with limited efficacy as well as at least in some cases added morbidity due to serious side effects. When a drug is repurposed with efficacy and safety demonstrated for other diseases, the timeline to availability to the patient population is reduced, the cost of production is lower, and the distribution channels are already in place.

Identifying SARS-CoV-2 proteins as essential targets for repurposable drugs: Out of many proteins (~29) known to be produced by the virus, there are several critical non-structural proteins in SARS-CoV-2 that are valuable targets for antiviral drugs as illustrated below.

In the coronaviridae family, a replicase is used to translate most of the viral genomic RNA to synthesize two replicase polyproteins, pp1a and pp1ab. These two polyproteins are processed by two proteases, (1) Papain-Like Protease (PLpro) and (2) , coronavirus 3-Chymotrypsin-Like Protease (3CLpro), generating 16 nonstructural proteins [14] [15] [16] . This proteolytic processing is essential for generating functional replication complexes [17] . As such, both PLpro and 3CLpro are promising antiviral targets and have already shown promise against COVID-19 in the drug combination therapy using lopinavir-ritonavir. PLpro has a core catalytic domain containing 316 amino acids. This protease cleaves the N-terminal region of the polyprotein to generate three different nonstructural proteins (1/2/3). PLpro is also suggested to have de-ubiquitinating activity, due to its structural similarities with cellular de-ubiquitinating enzymes [18] (Fig 2) . The enzyme 3CLpro contains a cysteine-histidine dimer within its active site that directs proteolytic activity. This protease can cleave 11 different sites of the replicase polyprotein to produce a mature protein that anchors replication/transcription complexes and releases mature NSPs. Structural analyses and computational screening with 3CLpro as a target have shown promising results for drug candidates against SARS-CoV [19, 20] .

(3) Viral non-structural protein (nsp) 14: Nsp14. Nsp14 has been implicated in SARS-CoV-2 as possessing two different activities: an exoribonuclease (ExoN) activity acting on both ssRNA and dsRNA in a 3' to 5' direction, and an N7-guanine methyltransferase activity (N7-MTase) [21, 22] . The activity of N7-MTase adds the N7-methyl guanosine cap during mRNA cap synthesis that is necessary for nsp16, activated by nsp10, to facilitate 2'-O-ribose methylation of the viral mRNA cap [23, 24] . 2'-O-Methylation is critical for CoV RNA to avoid host recognition [25, 26] . 2'-O-Methylation is further discussed below. ExoN activity has been suggested to be important for CoV replication and transcription, as well as for RNA proofreading during its replication. Using human CoV 229E and CoV murine hepatitis virus (MHV) respectively, Minskaia et al. (2006) and Eckerle et al. (2007) demonstrated that ExoN active-site mutants possess defects in viral RNA synthesis [22, 27] . Eckerle et al. (2007) additionally demonstrated that ExoN active-site mutants exhibit reduced replication fidelity [27] . Although there are no reports as of yet revealing drugs that target guanine-N7 methyltransferase (ExoN) of SARS-CoV or MERS-CoV, given that ExoN is important in coronaviruses for viral RNA synthesis and replication fidelity as well as for avoiding recognition of CoV RNA by the host, we assert it is to be a promising drug target ( Fig  2) .

(4) Nonstructural uridylate-specific endoribonuclease (NendoU) Nsp-15. NendoU activity is found in the N-terminal domain. This active site has been shown in MERS-CoV and SARS-CoV and is suggested to be a genetic marker common to coronaviruses. MERS-CoV Nsp16 appears to display unique features compared to its homologs. Nsp7/Nsp8 displays a higher binding affinity for Nsp15, also affecting enzymatic activity. Nsp15 from SARS-CoV appears to be an inhibitor of mitochondrial antiviral signaling adaptor, inducing apoptosis. Nsp15 activity is stimulated by manganese ions (Mn 2+) and the enzymes generate 2'-3' cyclic phosphate ends [28] . Nsp15 functions as a homohexamer, although the enzyme has some activity as a monomer [29] . The structures of MERS-Nsp15 and SARS-Nsp15 have been superimposed showing high homology [30] . Previous studies established that Nsp15 from both SARS-CoV and MHV can be stimulated by Mn 2+ [31] . The spatial arrangements revealed that residues S290 and Y339 in MERS-Nsp15 correspond to residues S293 and Y342 in SARS-Nsp15, which are postulated to interact with the substrate and confer uridylate specificity [31] , suggesting that there is conserved recognition for uridylate [30, 32, 33] .

Following the addition of the N7-methyl guanosine cap, nsp16, activated by nsp10, mediates mRNA cap 2'-O-ribose methylation to the 5'-cap structure of viral mRNAs. This has been shown in SARS-CoV and MERS-CoV and shown to be universal to coronaviruses [34, 35] . 2'-O-Methylation is important for the host immune system to discern self RNA from non-self RNA. Thus, through 2'-O-methylation of viral RNA, coronaviruses can subvert host innate immune responses by avoiding host recognition of their RNA [35] . Menachery et al. (2014) have demonstrated the requirement of 2'-O-methyltransferase (2'-O-MT) activity for SARS-CoV pathogenesis by characterizing deficient strain to have reduced viral titers and viral replication in-vitro and in-vivo (less weight loss and reduced breathing dysfunction in mice) [35] . Similarly, the importance of nsp16 and thus the activity of 2'-O-methyltransferase (2'-O-MT), has also been shown for MERS-CoV pathogenesis. Menachery et al. (2017) introduced mutations in the MERS-CoV NSP16 conserved KDKE motif, which resulted in significant attenuation of the viral load relative to the controls both in-vitro and in-vivo [34] . Despite there being no publication to date detailing drugs that target 2'-O-Methyltransferase to treat SARS-CoV or MERS-CoV, we are interested in 2'-O-MT as a potential drug target because of its role in avoiding recognition of CoV RNA by the host and its importance for SARS-CoV and MERS-CoV pathogenesis (Fig 2) .

(6) Viral helicase. Helicase is essential to viral genome replication and is therefore a potential target for antiviral drug development. Virus-encoded RNA helicases have important roles during viral life cycles for folding and replication of viral RNA [36] . As such, Nsp13 possesses NTPase and RNA helicases to facilitate hydrolysis of NTPs and unwind RNA (Fig 2) . In one study, it was demonstrated that myricetin and scutellarein are strong inhibitors of SARS-CoV helicase protein by affecting its ATPase activity [37] . Helicase is a multi-functional protein with a zinc-binding domain in the N-terminus displaying RNA and DNA duplex-unwinding activities with 5' to 3' polarity. The activity of helicase is dependent on magnesium (Mg 2+ ). As such, bismuth salts have been shown to inhibit NTPase and RNA helicase activities of SARS-CoV-2 nsp13 [9, 38] . Sequence annotation by Ivanov et al have shown that SARS-CoV nsp13 is divided into three domains: (A) an N-terminal Zn(II) binding domain and (B) a hinge domain, and (C) a helicase domain [28] [36] . Little is known of the viral nsp-12 activity, but activity occurs on two domains, on the N-terminal subunit NiRAN, and motif BN on the C-terminus. These sites have been shown in SARS-CoV and are suggested to apply to coronaviruses in general [39, 40] .

(7) RNA-directed RNA polymerase (RdRP). RDRP plays a critical RNA replication in RNA viruses due to its involvement in catalyzing template synthesis of polynucleotides in the 5'-3' direction. Further, RdRP is essential for the initiation of RNA replication in the host cell, a key step in the RNA viruses infection cycle [41, 42] . have demonstrated the importance of RdRP activity for SARS-CoV pathogenesis [43] . They showed that without RdRP, there is a complete disruption of SARS-CoV -RNA replication and viral growth halted (Fig 2) . Additionally, these authors also suggested that the hepatitis C drug EPCLUSA (Sofosbuvir/Velpatasvir) would target the active site of RdRP to inhibit coronaviruses [44] . RdRP is an established drug target for the treatment of SARS-CoV due to its role in viral RNA replication and its importance for SARS-CoV pathogenesis RdRP is of particular interest as a drug target.

Following in-silico HTVS, molecular modeling, MDS, and utilizing resources from the literature, we identified a series of potential lead molecules from the repurposable drug libraries against proteins that are critical for the ability of SARS-CoV-2 to infect and reproduce within the host cell (Tables 1-7) . Additionally, all of the simulated hit-target complexes were found to be strongly interacting and exhibited highly stable binding indicating the potential of being potent inhibitors of key SARS-CoV-2 enzymes and therefore promising candidates or leads for further development. Outputs from these analyses are presented in tables (Tables 1-7) and graphically (Top three interaction maps Supplementary Figs 1, 3, 5, 7, 9, 11&13) , and are discussed in the following sections. (Table 1) . Maltotetraose is an oligosaccharide of four units of alpha-D-glucopyranose linked by alpha- (1) (2) (3) (4) bonds. This is a sugar variant of a substance that is found to inhibit the growth and reproduction of bacteria [45, 46] . fig.2 ). Crocin/Crocetin are the major bioactive ingredients of saffron. There have been several studies that have shown the various efficacies of these drugs, including as neurotropic and chemotherapeutic agents [47, 48] . Crocin/Crocetin are popular agents to be tested in clinical settings due to their anti-oxidative properties [49] . Paclitaxel is a diterpene alkaloid natural product and belongs to a family of drugs that target tubulin leading to an abnormality of the mitotic spindle assembly, chromosome segregation, and consequently defects of cell division [50] . Paclitaxel is one of the most widely used anticancer drugs for the treatment of various cancers [51] . Other studies have shown that low doses of paclitaxel show promise in treating some non-cancer diseases including renal and hepatic fibrosis and artery restenosis [52] [53] [54] . NADH dianion is a species of NADH that arises from the deprotonation of the two diphosphates OH groups. Iohexol is a compound most well-known as a nonionic, water-soluble radiographic contrast medium used especially for renal disease determination. This compound is absorbed from the cerebrospinal fluid into the bloodstream and is eliminated by renal excretion. Heparin is a very interesting hit as it has been reported in multiple studies to increase the likelihood of survival of terminal COVID-19 patients [55, 56] by a mechanism that is not well understood but likely involves heparin's activity of reducing hypoxia as well via inhibiting the cytokine storm [57] . There is a minor report suggesting that hepcidin hormone mimics the spike protein of SARS-CoV2, [58] , and heparin is known to interfere with hepcidin [59] . This suggests that heparin's anti-COVID activity may present a multifaceted therapy option. MMGBSA re-ranking brought this molecule to the bottom despite a high glide energy score due to penalties exacted due to extra-active site exposure of the bulky compound. [61] . Interestingly, the highest-scoring among the aminoglycoside hits is Paromomycin which is an antiparasitic used to treat amoebiasis, visceral leishmaniasis, and cryptosporidiosis in immunocompromised patients. With the potential to treat pulmonary tuberculosis as well, the range of indications of this drug is indeed very wide and if found effective against COVID-19, it could prove to be a valuable addition to the arsenal of combination therapies. The Paromomycin RdRP complex was simulated for 20ns and the interaction was highly stable throughout the simulation validating the pipeline for RdRP (Supplementary fig.4 ).

Lactulose is a synthetic disaccharide of galactose and fructose which can be produced by the isomerization of lactose. This compound has been used for treating bacterial infections, constipation, and cancer. An important note on lactulose is that it is not hydrolyzed by mammalian enzymes, therefore, ingested lactulose passes through the stomach and small intestine without degradation [62] . Framycetin is an aminoglycoside antibiotic isolated from Streptomyces lavendula that shows broad-spectrum antibacterial activity. This drug has been used as a therapeutic against a variety of cancers [63, 64] . Amikacin is an aminoglycoside antibiotic that is on the WHO list of essential medicines. It is a prokaryotic translation inhibitor that binds to the 16S ribosomal subunit. Bekanamycin is another aminoglycoside that inhibits prokaryotic translation by binding to the highly conserved A site of 16S rRNA in the 30S ribosomal subunit. This compound has the lowest antibacterial activity of the aminoglycosides in clinical use and manifests a moderate level of toxicity, therefore, it is no longer used as a first-line antibiotic [65] . Lividomycin A is an aminoglycoside that shows antibiotic activity against several of the Gram+/bacteria by inhibiting protein synthesis [66] . Lapatinib ditosylate is the salt of Lapatinib, a synthetic quinazoline that blocks the phosphorylation of various epidermal growth factor receptors and inhibits cyclin D protein levels in human tumor xenografts and cell lines [67, 68] . Uridylate-specific endoribonuclease (NendoU) Hits (Table 3) in several Legumimosae such as the Japanese Kudzu root and is the 7-O-glucoside of the isoflavone daidzein. It is shown to have anticancer and antiallergenic activities [69] . Daidzein and Haloperidol have been identified in multiple virtual screenings [70, 71] . MD Simulation of the Daidzin-NendoU complex for 20ns revealed a stable and energetically favorable interaction and validated the pipeline for the NendoU virtual screening (Supplementary fig.6 ). SCHEMBL24383 (Active principle of Strychnos potatorum Linn. seed extracts) has been extensively used to combat respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. Interestingly, given its predicted anti-COVID-19 activity, it may result in a dual therapeutic potential drug. Metrizamide is a non-ionic iodine-based radiocontrast agent that is widely used in lumbar myelography [72] . Haloperidol glucuronide is a metabolite of the commonly prescribed antipsychotic drug on the WHO's list of Essential Medicines. Haloperidol is used in the treatment of schizophrenia, mania in bipolar, delirium, and other neurological diseases [73, 74] and is on the WHO's List of Essential Medicines. 4-Hydroxy phenytoin glucuronide is a metabolite of the widely used antiepileptic phenytoin. The adverse effects of phenytoin can range from moderate diseases including gingival hyperplasia to severe more effects including toxic epidermal necrolysis and teratogenic effects [75] . Similarly, acetaminophen O-β-D-glucose iduronate is a metabolite of acetaminophen generated in the liver by UDPglucuronyltransferase. It is highly water-soluble and is excreted through the kidneys. Acetaminophen was recommended by WHO in the case of COVID-19 due to a concern over ibuprofen being an ACE2 inhibitor that might increase viral entry [76] . The advisory was subsequently revised to state that both medications are appropriate [77] . A metabolite of acetaminophen could prove to be an added advantage of already being used as a drug. p-Aminophenyl-alpha-D-galactopyranoside is an experimental phenolic glycoside that competitively binds to heat-labile enterotoxin B pentamers by mimicking host cell receptors (intracellular adenylyl cyclase) [78] . 7 .' Diosmin is a flavone glycoside that is mostly found in citrus fruits. It is a non-prescribed dietary supplement that is primarily used for venous diseases, although there is limited clinical data to support its efficacy. Common adverse effects include mild gastrointestinal disturbances and cardiac arrhythmias [79] . Interestingly other studies have reported diosmin to be a coronavirus main protease inhibitor. MD Simulations for 20 ns with Diosmin-ExoN complex revealed a very strong binding establishing the target specificity of Diosmin and validated the screening pipeline with ExoN (Supplementary fig.8 ). Hidrosmin is a synthetic bioflavonoid that is used to treat chronic venous insufficiency of the lower limbs [80] . A crude preparation of Diosmin and Hidrosmin has been determined to be effective against COVID-19 [81] . N-Desmethyl-4-hydroxy tamoxifen beta-D-glucuronide (E/Z Mixture) has also been identified as a strong binding ligand. Tamoxifen has also been proposed as an anti-COVID-19 drug as it can induce autophagy associated with the unfolded protein response to kill infected cells and thus contain the virus [82] . Octane-1,3,5,7-tetracarboxylic acid B belongs to the class of zinc ion binding compounds that target Carboxypeptidase A1. Bempedoic acid is a prodrug that is converted to its active form in the liver. It is an FDA approved treatment for hypercholesterolemia and has few adverse effects. This compound inhibits adenosine triphosphate citrate lyase, an enzyme within the cholesterol biosynthesis pathway [83] . Bisindolylmaleimide IX (BIM IX) a was strongly bound to ExoN active site for a 100 ns simulation ( Fig 4& Fig 5(B) ) and the stable complex had a tight binding with the whole molecule involved in interactions with 3CLpro active site side-chain amino acid residues (Fig 4(B)& Fig 5(B) ). Helicase (HEL) Hits (Table 5) . Ligand interaction maps of the top 3 hits are shown in ' Supplementary fig. 9 .' The FDA approved drug ivermectin recently showed significant anti-SARS-CoV-2 antiviral activity, suggesting its therapeutic potential [84] . While the target of ivermectin in SARS-CoV-2 is yet to be confirmed, it has been reported that its antiviral activity in the case of flaviviruses, particularly the Australian Kunjin virus (West Nile virus variant) [85] is based on targeting viral helicases. While our screening did not show ivermectin as a top helicase inhibitor, its binding activity established viral helicase as an important target in SARS-CoV-2. We found several small-molecule compounds including inosine, 5-F-UMP, fenoterol, didanosine, and doxifluridine as potential helicase inhibitors. While Inosine, 5-F-UMP, and fenoterol have a high affinity towards the ATP-Nucleic acid interface, our top target against Helicase is inosine. Inosine is a nucleoside commonly found in tRNAs and is essential for proper translation of the genetic code in wobble base pairs. It has been tried in various clinical settings, most notably in multiple sclerosis [86] . MD Simulations for 20 ns with the Helicase-Inosine docked complex revealed a very strong binding establishing the target specificity of Inosine and validated the screening pipeline with HEL (Supplementary fig.10 ). 5-F-UMP is a pyrimidine ribonucleoside 5'monophosphate having 5-fluorouracil as the pyrimidine component. It shows antineoplastic activity by being inorporated in RNA and it inhibits RNA processing, thereby inhibiting cell growth. Fenoterol is a β adrenoreceptor agonist that is used as an inhaled bronchodilator asthma medication [87] . Didanosine is particularly interesting as it is a reverse transcriptase (HIV) inhibitor [88] . Also, Didanosine has been profiled as a beneficial drug in the case of the COVID-19 type of lung fibrosis by matching single-cell RNA sequencing data [89] . Inhibition of inosine-5'-monophosphate dehydrogenase (IMPDH) has been shown to control SARS-CoV-2 replication [90] , which could be due to inosine accumulation. Didanosine is also a medication used to slow the progress of HIV/AIDS and is a nucleoside analog of adenosine. There are several common adverse effects associated with this medication including diarrhea, vomiting, and peripheral neuropathy [91] . Fenoterol has already been recommended to reduce severe pulmonary symptoms of COVID-19 patients [92] . Doxifluridine has been suggested as a possible SARS-CoV-2 inhibitor based on similarities with active antivirals already tested by artificial intelligence [93] . Doxifluridine is a nucleoside analog prodrug that interferes with RNA transcription by competing with uridine triphosphate for incorporation into the RNA strand. It is used as a cytostatic agent in chemotherapy in several countries in Asia [94] . Papain-like proteinase (PLpro) Hits ( Table 6 ). The ligand interaction maps of the top 3 hits are shown in ' Supplementary fig. 11 .' Troxerutin is a naturally occurring flavonoid that has been reported to show promise as a vasoprotective agent by improving hepatic homeostasis [95] . There have been many in silico drug screening efforts with the coronavirus Main Protease that have predicted troxerutin as a potential inhibitor of 3Clpro [96] . Also, the famous 'Chai-Ling decoction' a Chinese medicine herbal formulation with reported protection from SARS, MERS, and now COVID-19 has troxerutin as a major component [97, 98] . MD Simulations for 20 ns with troxerutin-PLpro docked complex revealed a very strong binding establishing the target specificity of troxerutin and validated the screening pipeline with PLpro (Supplementary fig.12 ). The identified hit 4-O-(4,6-dideoxy-4-{[4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1yl]amino}-beta-D-lyxo-hexopyranosyl)-alpha-D-erythro-hexopyranose is an aminocyclitol glycoside, as well as 4,6-dideoxy-4-{[4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1yl]amino}-aapha-D-lyxo-hexopyranosyl-(1->4)-alpha-D-threo-hexopyranosyl-(1->6)-alpha-Lthreo-hexopyranose have been shown to target pancreatic alpha-amylase [99] . Both of these compounds belong to the class of aminocyclitol glycosides similar to streptomycin. This class of compounds has been used previously to target the RNA metabolism of viruses [100] . Hyaluronic acid is a non-sulfated glycosaminoglycan (GAG) and is composed of repeating polymeric disaccharides of D-glucuronic acid and N-acetyl-D-glucosamine linked by a glucuonidic β (1→3) bond [101] . It is a key molecule involved in skin moisture that can retain water. Monoxerutin is another flavonoid which has been patented to be used against Hepatitis C [102] . Anastrozole is an aromatase inhibitor approved by the FDA to treat postmenopausal women diagnosed with hormone receptor-positive breast cancer at advanced-stage or early-stage after surgery [103, 104] . (Table 7) . Ligand interaction maps of the top 3 hits are shown in ' Supplementary fig. 13 .' XAV-939 is a beta-catenin signaling inhibitor that has been shown to have promise in treating prostate cancer [105] . XAV-939 is also an effective inhibitor of PARP and Wnt pathway. PARPs enhance IFNγ production and can halt viral infections [106, 107] . Thus, a dual-mode of action is expected of XAV-939 if it is found to inhibit the main protease as well. MD Simulation of XAV-939-3CLpro docked complex for 100ns revealed a stable and energetically favorable interaction and validated the pipeline for the 3CLpro virtual screening (Supplementary fig.14) . Crocin is a carotenoid diester that is responsible for the color of saffron and is popularly used in India as a treatment for arthritis and psychological disorders [108] .

Loperamide is used to treat gastrointestinal symptoms including diarrhea with few side effects and is on the WHO's List of Essential Medicines. Isoquercetin is a flavonoid natural product that can be isolated from various plant species and has shown promise as an anti-cancer agent [109] .

Danoprevir is a 15-membered ring macrocyclic peptidomimetic inhibitor of the hepatitis C protease NS3/4A [110] . Other virtual drug screenings have reported danoprevir as a possible coronavirus main protease inhibitor [111] . In clinical trials, danoprevir had a positive effect on recovery and faster discharge of COVID-19 patients [112] . Cefoperazone is a cephalosporin antibiotic. It is one of the few cephalosporin antibiotics effective in treating Pseudomonas bacterial infections [113] . In China, most of the treatment regimens reported using cefoperazone to prevent secondary infections in COVID-19 patients [114, 115] . Nevirapine is a non-nucleoside reversetranscriptase inhibitor [116] . This compound is FDA approved for use in adult patients infected with HIV-1. Nevirapine has also been revealed in various in-silico drug screening with the main protease [117, 118] . Pentostatin is a purine analog that is widely used as a treatment for hairy cell leukemia [119] . Similar to pentostatin, cladribine is also a therapy for hairy cell leukemia. And also like nevirapine, cladribine has been predicted to block main protease 3CLpro in many reports [118, 120] . Bisindolylmaleimide IX a PKC inhibitor, strongly bound to 3CLpro for a 100 ns simulation (Fig 3 & Fig 5(A) ), and the stable complex exhibited a tight binding with the whole molecule involved in interactions with 3CLpro active site side-chain amino acid residues (Fig 3(B) & Fig 5(A) ). (Figs 6 and 7) . Lactulose & Iopromide had no observed inhibitory activity, which could be due to low intracellular accumulation as Lactulose is anti-diarrhea and Iopromide is an MRI contrast agent. This supports the predicted interaction and MOA and can be used to improve or screen more members from the same chemotypes and similar pharmacophore. Lactulose (Anti-Diarrhea) and Iopromide (MRI contrast) both showed no activity at the concentration range tested. This could be due to a lack of cell permeability as both are not used for intracellular functions. An inhibitory concentration (IC50) was estimated by curve fitting over linear regression of Log10 drug concentrations vs. normalized data (percentage, Table 8 ). The IC50 was plotted on the variable slope of the drug responses (Figs 6 and 7) . Bisindolylmaleimide derivatives are widely used as inhibitors of protein kinase C (PKC) isoforms. Bisindolylmaleimide IX (BIM IX), also known as Ro 31-8220, is an advanced investigational molecule and one of the most commonly used PKC inhibitor standards [121] . BIM IX is an imidothio carbamic ester, as well as a bis-indole maleimide. Several reported pharmacological effects of BIM IX; stimulation of c-Jun-N-terminal kinase (JNK) expression, an activator of p38 MAPK through phosphorylation; activation of glycogen synthase activity in adipocytes, among other effects [122] [123] [124] . BIM IX shows potent inhibition of PKC α, PKC βI, PKC βII, PKC γ, and PKC ε [125] . BIM IX also inhibits MSK1, MAPKAPK1, RSK, GSK3β, and S6K1 with a potency similar to that for PKC [125] . BIM IX significantly decreases apoE secretion from primary human macrophages by inhibiting vesicular transport of apoE to the plasma membrane without significantly affecting apoE mRNA or apoE protein levels [125] . Bim IX has been extensively studied in several animals and human tissue types showing a safe profile [126] [127] [128] . In the context of SARS CoV2, the anti-inflammatory and anti-bronchitis profile of this molecule may prove to be an additional therapeutic advantage [127] . While the effect of PKC inhibition on this particular virus is not known, but the SARS-CoV pathogenesis profile is known to be greatly dependent on PKC [129, 130] .

To characterize the mechanistic aspects of BIM IX activity, biochemical studies of the 3CLpro enzyme-inhibitor complex were performed. We used a peptide substrate with a C-terminal 7-amino-4-methyl-coumarin (AMC) with a fluorogenic reporter group to perform kinetic assays of 3CLpro inhibition. BIM IX and Haloperidol were tested at four concentrations and the rate of substrate cleavage was recorded at different time points (Fig.8) . Haloperidol had a very mild activity, while BIM IX had significant activity. Finally, BIM IX concentrations were varied relative to a fixed concentration of the peptide substrate and monitored over time. Inhibition was observed with an IC50 value of 113.7 ± 5.2 µM (Fig.9 ).

The rapid spread of SARS-CoV-2 continues to create havoc in health systems and economies, affected every nation around the world. As this is a novel coronavirus, vaccines are being developed at an unprecedented pace and we must also resort to the rapid development of therapeutics for COVID-19. There has been an international focus on the potential efficacy of repurposable drug candidates including remdesivir and hydroxychloroquine, among others. With each controlled clinical study that comes out, it becomes more evident that nations were too quick to push certain compounds, consequently reducing the supply to patients who needed them to treat already indicated diseases [131] . There is a possibility that these compounds may still have a place in the clinical realm as a treatment for COVID-19, but not as stand-alone therapies as currently utilized. Until a SARS-CoV-2 specific compound is developed and clinically approved, the best way is to find treatment through a multifaceted approach of repurposing as well as developing new drugs. This philosophy is at the forefront of our work, first by screening approved compounds for repurposing potential, and by identifying the best possible combinations providing a possible treatment for SARS-CoV-2.

In this context, we commenced a CADD through the HTVS approach using a large pool of world approved drug libraries to identify potential drugs for immediate deployment (Fig.1 ). Our in-silico studies have shortlisted a series of repurposable drugs that can be utilized in clinical trials. From our eight selected approved compounds that underwent in-vitro studies against SARS-CoV-2, we found two compounds with high inhibitory activity. One of these was ivermectin, which showed significant viral inhibition, confirming the results of a previous study [84] . Like previous reports, our in-vitro studies found that ivermectin has nonselective toxicity to the ATCC E6 Vero cells at ≤50 μM and 16.67 μM based on the number of nuclei counted. This shows that high doses (>16.67 μM) of ivermectin have high cytotoxicity as reported by other groups [132, 133] , and this must be considered when preparing to use this drug in COVID-19 clinical trials as its currently approved dosage is very low (25mg) [134] . The second compound with significant inhibitory activity against in-vitro SARS-CoV-2 was bisindolylmaleimide IX. Further, BIM IX specifically blocked 3CLpro in-vitro enzymatic assay confirming the robustness of our in-silico prediction pipeline. Higher activity in entry assays of 3CLpro inhibitors points to its high activity as once it is expressed in sufficient amounts partial inhibition has a diminished effect or viral replication. This is a critique for high throughput screening assays (spread assay format) as they might miss inhibitors for this target. The target-specific high throughput screenings (both enzymetic and anti-viral) are needed to be designed with parallel toxicity screens for better drug repurposing screens. Overall, this is the first study that showcases the possibility of using bisindolylmaleimide IX specific derivatives and an urgent need to further evaluate their suitability to advance to clinical use to treat COVID-19.

The crystal structures of NSP3 (PDB ID-6W02), NSP9(PDB ID-6W4B), NSP15 (PDB ID-6VWW) from SARS CoV-2 were obtained from Protein Data Bank [135] . The crystal structures of COVID-19 main protease (NSP5) in complex with Z44592329 (ID:5r83) were obtained from the Protein Structure Database of Europe [136] . QHD43415 [9] : the I-TASSER models were obtained for NSP3(QHD43415_3), NSP5 (QHD43415_5), NSP11(QHD43415_11), NSP12 (QHD43415_12), NSP13(QHD43415_13), and NSP14 (QHD43415_14) [9] .

Protein preparation was performed using the Protein Preparation Wizard in Maestro [10] . All co-crystallized atoms including calcium and chlorine were deleted. Co-crystalized ligands within the active site were not deleted because they were used for grid generation. All water with less than 3 hydrogen bonds (Sample water orientation) with 'non-waters' i.e. receptor protein or ligand were deleted. Each of the seven models developed was subjected to preparation by the Wizard in Maestro [10] . Each of the complexes was optimized with minimized hydrogens of altered species and then minimized using the OPLS3e force field [10, 137] . Further, the models were subjected to MD simulation (MDS) after solvation in water and 0.15M NaCl (physiological solution). A simulation box covering the entire enzyme system was introduced with a 10 Å buffer space. The simulation was run for 100 ns at 300 K and standard pressure (1.01325 bar). The target complex trajectory analysis for interacting residues and was conducted using the Desmond software [10] .

A virtual library of n=5903 drug compounds was downloaded from the latest Zinc database [11] under the 'world' subset (approved drugs in major jurisdictions, including the FDA, i.e DrugBank approved). The database was then checked for redundancy, and duplicates were removed. Ligand preparation was performed using LigPrep, which generated variations of the ligands, eliminated reactive species, and optimized the ligands. Optimization was performed under the OPLS3e force field. EPIK minimization was performed on possible states at pH 7.0 ±2.0. Tautomers were generated for each ligand retaining specific chirality combinations with a maximum of 32 structures per ligand [10] .

Receptor grid generation. COACH analysis was performed to determine the location and size of the active site [138] . The shape and properties of the receptor are represented on a grid to ensure that possible active compounds are not missed. The centroid of the COACH predicted binding pocket residues and was used to generate grids using default values of protein atom scaling (1.0 Å) within a cubic box and ligand docking set to a length of 20Å. The force field employed for grid generation was OPLS3e [137] . Rotatable groups were automatically determined by the Receptor Grid Generation wizard of the Glide module [10] . COACH predicted binding sites for each target were as follows; Exoribonuclease (ExoN); Based on the active site similarity with PDB ID : 5C8T, S-Adenosyl-L-Methionine ( 

The screening was performed with default parameters including ionization states, Epik state penalties within the Glide (Grid-based ligand docking from energetics) module of Schrödinger suite [139] . The scaling factor was maintained at a default of 0.8 and a partial charge cut-off was limited to 0.15. The OPLS3e force field was used during the docking process. The HTVS ligand docking was the first to be performed, followed by SP and XP docking on the top 10% of scoring hits from each previous step. The XP docking aids in removing false positives and the scoring function is much stricter than the HTVS. The greater the XP Glide score, the better the calculated affinity of the hit in binding to the protein target. Further, the estimation of free binding energies for the best hit-docked complexes using MM force fields and implicit solvation was performed using the molecular mechanics/generalized Born surface area (MM-GBSA) method within the virtual screening workflow of Schrödinger suite [10] . The binding energy was calculated based on the following equation.

The leads were ranked based on the binding free energy calculation for their respective proteinligand complexes.

To determine the stability of the ligand-receptor complex especially during flexibility of the binding site and to determine the energetic strain on the docked ligand that could result in immediate fly off (<10ns). The top hit for each target was subjected to a 20 ns MD simulation (100 ns for XAV-939 + 3CLpro, BIM IX + 3CLpro, & BIM IX + ExoN) as described above in the Target/receptor Preparation section to validate the interaction and thereby the HTVS pipeline and MM-GBSA performance. If the top hit flew off immediately due to major conformation change in the receptor site then the receptor was stimulated alone for 20ns to reach a stable state and screening was repeated with the resulting minimized structure. , then permeabilized with 0.2% Triton-X for 10 min at RT and treated with blocking solution (3% BSA/PBS). Infected cells were detected using a primary detection antibody recognizing the SARS-CoV-2 nucleocapsid protein (Sino Biological, 40143-R001) and Alexa Fluor 488 conjugated antibody (goat α rabbit), then counterstained with DAPI for visualization of the cell nuclei. Infected cells were enumerated using the Operetta high content imaging instrument and data analysis was performed using the Harmony software (Perkin Elmer). Spread Assay: A similar protocol was utilized to the entry assay described above with the following modifications. The virus was used at an MOI of 0.02 and the assay was incubated for 48 hrs. rather than 24 hr. after infection of the cells. The authors declare no conflict of interest.

Author Contributions. YG and PK designed the study and performed in-silico analysis. DM, RM, CMP, DJI, and HH assisted in data mining, virtual screening, related in-silico analysis, and table generations for drug characteristics. DM, CMP, and YG covered the epidemiology, virus, genome, and target protein background. PK, AB, and RD contributed to the clinical aspects of the study. DPB, YG, and BR contributed to the chemical and molecular aspects of leads. ASH, SEZ, and JMD performed in-vitro testing against the SARS-CoV-2 virus and toxicity data. BD, KAJ, RSK, and SA synthesized fluorescent probe for 3CLpro and performed biochemical assays and assisted with the mechanistic aspects, and validated the viral target and lead interactions. All authors contributed to writing the manuscript. receptor. An S1-induced post-stable S2 conformation allows either viral-host cell fusion (1a) or endocytosis (1b). Fusion directly allows the viral RNA to enter the host cell (2), but endocytosis requires lysosomal degradation of coat and envelop for the release of viral nucleocapsid in the cytoplasm. The large viral script is known to encode 29 viral proteins (3), including the 7 essential nonstructural proteins that are selected as targets in our paper. A replicase is used to translate most of the viral genomic RNA to synthesize two replicase polyproteins, pp1a and pp1ab, and many small ORFs(4). The two major polyproteins are processed by two proteases, PLpro and 3CLpro (5), generating 16 nonstructural proteins. ExoN possesses a viral exoribonuclease activity that acts on both ssRNA and dsRNA in a 3' to 5' direction (9) . Viral Helicase plays a critical role in viral replication by expediting appropriate folding (7) . The enzyme 2'-O-MT methylates the viral 2' end which is important for the virion to avoid host recognition of their RNA (8) . RdRP is involved in viral-host cell replication through catalyzing template synthesis of polynucleotides in the 5' to 3' direction (7) . NendoU is an Mn 2+ dependent hexamer (dimer of trimer) enzyme with sparse functional information. The most prominent theory regarding NendoU is that the activity of this protein is responsible for protein interference with the innate immune system. For viral assembly of S, E, and M proteins in the endoplasmic reticulum, along with the N protein are combined with the (+) gRNA to become a helical nucleoprotein complex. They assemble to form a virus particle in the endoplasmic reticulum-Golgi apparatus compartment, this particle is then excreted from the cell through budding mediated by fusion of smooth-walled vesicles to the plasma membrane (11) (12) . (Table 5) : A) daidzin, B) phenytoin glucuronide, and C) haloperidol glucuronide within the Uridylate-specific endoribonuclease (NendoU) binding pocket as determined by (Schrödinger LLC_2020-1) depicting amino acid side chain residues colored according to their biochemical nature i.e. red = acidic, violet = basic, green = hydrophilic, and light blue = hydrophobic. The bold lines depict peptide backbone and red arrows depict molecular interactions. The bold lines depict peptide backbone and red arrows depict molecular interactions.

(A) (B) (C) (D)

Supplementary fig.7 . 2D Ligand interaction maps of the top 3 hits (Table 6 ) within the Guanine-N7 methyltransferase (ExoN) binding pocket (Schrödinger LLC_2020-1) depicting amino acid side chain residues colored according to their biochemical nature i.e. red = acidic, violet = basic, green = hydrophilic, and light blue = hydrophobic. The bold lines depict peptide backbone and red arrows depict molecular interactions. (Table 8) within Papain-like proteinase (PlPro) binding pocket (Schrödinger LLC_2020-1) depicting amino acid side chain residues colored according to their biochemical nature i.e. red = acidic, violet = basic, green = hydrophilic, and light blue = hydrophobic.

The bold lines depict peptide backbone and red arrows depict molecular interactions. binding pocket (Schrödinger LLC_2020-1) depicting amino acid side chain residues colored according to their biochemical nature i.e. red = acidic, violet = basic, green = hydrophilic, and light blue = hydrophobic. The bold lines depict peptide backbone and red arrows depict molecular interactions.

others, Clinical features of patients infected with 2019 novel coronavirus in

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Organization, others, Coronavirus disease ( COVID-19): situation report

Coronavirus genomic RNA packaging

Coronavirus infection in equines: A review

Emergence of COVID-19 (formerly 2019-novel Coronavirus): a new threat from China

Middle East respiratory syndrome, The Lancet

Snijder, others, Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans

Protein structure and sequence reanalysis of 2019-nCoV genome does not indicate snakes as its intermediate host or the unique similarity between its spike protein insertions and HIV-1

Small-Molecule Drug Discovery Suite

ZINC-a free database of commercially available compounds for virtual screening

A bibliometric review of drug repurposing

Middle East respiratory syndrome-coronavirus (MERS-CoV): an updated overview and pharmacotherapeutics

of the International, others, The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak

Hiscox, others, Characterisation of the transcriptome and proteome of SARS-CoV-2 using direct RNA sequencing and tandem mass spectrometry reveals evidence for a cell passage induced in-frame deletion in the spike glycoprotein that removes the furin-like cleavage site

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response

The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity

Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors

Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs

Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase

Discovery of an RNA virus 3′→ 5′ exoribonuclease that is critically involved in coronavirus RNA synthesis

In vitro reconstitution of SARS-coronavirus mRNA cap methylation

Ahola, others, Coronavirus nsp10/nsp16 methyltransferase can be targeted by nsp10-derived peptide in vitro and in vivo to reduce replication and pathogenesis

Dong, others, 2′-O methylation of the viral mRNA cap evades host restriction by IFIT family members

others, Ribose 2′-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5

High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants

Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase

SARS coronavirus replicative enzymes: structures and mechanisms

Structural and biochemical characterization of endoribonuclease Nsp15 encoded by Middle East respiratory syndrome coronavirus

SITE DIRECTED MUTAGENESIS OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) CORONAVIRUS NSP 15 ENDORIBONUCLEASE

The severe acute respiratory syndrome coronavirus Nsp15 protein is an endoribonuclease that prefers manganese as a cofactor

MAVS-mediated apoptosis and its inhibition by viral proteins

Middle east respiratory syndrome coronavirus nonstructural protein 16 is necessary for interferon resistance and viral pathogenesis

Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2′-O-methyltransferase activity

Structural and biochemical basis for the difference in the helicase activity of two different constructs of SARS-CoV helicase

Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13

others, SARS-coronavirus-2 nsp13 possesses NTPase and RNA helicase activities

Qi, others, Structural and biochemical characterization of nsp12-nsp7-nsp8 core polymerase complex from COVID-19 virus

Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors

Structural analysis of inhibition mechanisms of aurintricarboxylic acid on SARS-CoV polymerase and other proteins

Nidovirus RNA polymerases: complex enzymes handling exceptional RNA genomes

Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19

Nucleotide Analogues as Inhibitors of SARS-CoV Polymerase

Amylases and their applications

Maltotetraose-producing amylase from Bacillus sp. MG-4, Agric

Cancer chemopreventive and tumoricidal properties of saffron (Crocus sativus L.)

The effects of resuscitation with trans-sodium crocetinate in a model of combined hemorrhagic shock and traumatic brain injury

Crocetin protects against oxidative damage in rat primary hepatocytes

Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied

The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents

Paclitaxel ameliorates fibrosis in hepatic stellate cells via inhibition of TGF-β/Smad activity

Yang, others, Lowdose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192

Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Deng, others, The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective clinical study

Heparin therapy improving hypoxia in COVID-19 patients-a case series

Distant sequence similarity between hepcidin and the novel coronavirus spike glycoprotein: a potential hint at the possibility of local iron dysregulation in COVID-19

Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo

Aminoglycoside antibiotics bind to the influenza A virus RNA promoter

Anti-HCV Drug Development

Die intestinal-enzymatische Spaltung von Galakto-Oligosacchariden im Darm von Tier und Mensch mit besonderer Berücksichtigung von Lactobacillus bifidus 2. Mitt. Zum intestinalen Verhalten der Lactulose

Neomycin inhibits the angiogenic activity of fibroblast and epidermal growth factors

Neamine inhibits oral cancer progression by suppressing angiogenin-mediated angiogenesis and cancer cell proliferation

Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice?

Mode of action of lividomycin on protein synthesis in Escherichia coli

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label

others, Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

Suppressive effects of dietary genistin and daidzin on rat prostate carcinogenesis

In silico Screening of Food Bioactive Compounds to Predict Potential Inhibitors of COVID-19 Main protease (Mpro) and RNA-dependent RNA polymerase (RdRp)

Dange, others, Computational Drug Simulation: A step to the possible cure of COVID-19

Lumbar myelography with metrizamide in rabbits: an investigation of contrast media penetration and resorption

Pharmacokinetics of haloperidol

Recognition and management of withdrawal delirium

PharmGKB summary: caffeine pathway

Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists

Misguided drug advice for COVID-19

Exploration of the GM1 receptor-binding site of heat-labile enterotoxin and cholera toxin by phenyl-ring-containing galactose derivatives

Clinical trial of oral diosmin (Daflon®) in the treatment of hemorrhoids

Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs

Accelerated production of hesperidin-rich citrus pectin from waste citrus peel for prevention and therapy of COVID-19

Focusing on the unfolded protein response and autophagy related pathways to reposition common approved drugs against COVID-19

Groot, others, Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis

The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro

Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug

Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease

Fenoterol: A Beta2-adrenergic Agonist for Use in Asthma; Pharmacology, Pharmacokinetics, Clinical Efficacy and Adverse Effects

Beall, others, A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection

Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data

The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro

Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection

Suggestions for second-pass anti-COVID-19 drugs based on the Artificial Intelligence measures of molecular similarity, shape and pharmacophore distribution

The pharmacokinetics of doxifluridine and 5-fluorouracil after single intravenous infusions of doxifluridine to patients with colorectal cancer

Troxerutin improves hepatic lipid homeostasis by restoring NAD+-depletion-mediated dysfunction of lipin 1 signaling in high-fat diet-treated mice

Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach

Therapeutic effect of chai-ling-tang (sairei-to) on the steroid-dependent nephrotic syndrome in children

others, Network pharmacology studies on the effect of Chai-Ling decoction in coronavirus disease 2019

Subsite mapping of the human pancreatic α-amylase active site through structural, kinetic, and mutagenesis techniques

Targeting HIV-1 RNA with Aminoglycoside antibiotics and their derivatives

The structure of hyalobiuronic acid and of hyaluronic acid from umbilical Cord1, 2

Treatment of hepatitis C virus infection using a protease and a flavonoid

Clinical pharmacokinetics of aromatase inhibitors and inactivators

The WNT/β-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro

The coronavirus macrodomain is required to prevent PARP-mediated inhibition of virus replication and enhancement of IFN expression

The Viral Macrodomain Counters Host Antiviral ADP-Ribosylation

The effects of crocin on psychological parameters in patients under methadone maintenance treatment: a randomized clinical trial

Review of anticancer mechanisms of isoquercitin

Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a-Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders

Virtual Screening based prediction of potential drugs for COVID-19

Chen, others, First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients

Pharmacokinetics and pharmacodynamics of cefoperazone-sulbactam in patients on continuous ambulatory peritoneal dialysis

Clinical features and outcomes of 221 patients with COVID-19 in

Yu, others, Early release-lack of vertical transmission of severe acute respiratory syndrome coronavirus 2

Pharmacological and clinical evidence of nevirapine immediate-and extended-release formulations

Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning

Computational screening and identifying binding interaction of anti-viral and anti-malarial drugs: Toward the potential cure for SARS-CoV-2

Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective

Binding mechanism of remdesivir to SARS-CoV-2 RNA dependent RNA polymerase

Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C

The selective protein kinase C inhibitor, Ro-31-8220, inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) expression, induces c-Jun expression, and activates Jun N-terminal kinase

C3 toxin activates the stress signaling pathways, JNK and p38, but antagonizes the activation of AP-1 in rat-1 cells

RO 31-8220 activates c-Jun N-terminal kinase and glycogen synthase in rat adipocytes and L6 myotubes. Comparison to actions of insulin

The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase-1β (Rsk-2) and p70 S6 kinase

Differences in sensitivity to the specific protein kinase C inhibitor Ro31-8220 between small and large bronchioles of the rat

Thrombin promotes endothelial cell alignment in Matrigel in vitro and angiogenesis in vivo

others, SARS-CoV proteins decrease levels and activity of human ENaC via activation of distinct PKC isoforms

Nie, others, SARS-CoV proteins decrease levels and activity of human

Preziosi, others, Repurposed antiviral drugs for COVID-19

Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens

The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Feng, others, The RCSB protein data bank: integrative view of protein, gene and 3D structural information

PDBe-KB: a community-driven resource for structural and functional annotations

OPLS3e: Extending force field coverage for drug-like small molecules

COACH-D: improved protein-ligand binding sites prediction with refined ligand-binding poses through molecular docking

Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes

Fig 9. 3CLpro inhibition assay. Fluorescence-based biochemical activity assay for BIM IX using the TVLQ-AMC probe substrate. All values are mean ± standard deviation with n = 3 replicates

The authors sincerely thank the Department of Medicine, Loyola University Medical Center, and Stritch School of Medicine for supporting the Drug Discovery Program and the High Computing Platform. This project was also supported by the Research Funding Committee (RFC), Loyola University Chicago (PK, LU#213627). Opinions, discussions, conclusions, interpretations, and recommendations are those of the authors and are not necessarily endorsed by the U.S. Army. The mention of trade names or commercial products does not constitute endorsement or recommendation for use by the Department of the Army or the Department of Defense.

The authors declare no conflict of interest. Seven enzymes of Covid19 virus proteome were comprehensively targeted; 3CLPro, PlPro, RdRP, Helicase, NandoU, ExoN and 2O-MT  Virtual screening (VS) was performed with world approved/investigational drug libraries (n=5903)  Two tier anti-viral assay with nuclei counting for reliable activity  Bisindolylmaleimide IX reported here is an advanced investigational molecule and has 80% viral blocking at 50 µM  Specific highly sensitive FRET based main protease (3ClPro) enzymatic assays